Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer

Jing Zhao, Regina M. Day, JianYue Jin, Leslie Quint, Hadyn T Williams, Catherine Lowrie Ferguson, Li Yan, Maurice King, Ahmad Albsheer, Martha Matuszak, Feng Ming Kong

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The risk factors and potential practice implications of radiation-induced pleural effusion (RIPE) are undefined. This study examined lung cancer patients treated with thoracic radiation therapy (TRT) having follow-up computed tomography (CT) or 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Increased volumes of pleural effusion after TRT without evidence of tumor progression was considered RIPE. Parameters of lung dose-volume histogram including percent volumes irradiated with 5-55 Gy (V5-V55) and mean lung dose (MLD) were analyzed by receiver operating characteristic analysis. Clinical and treatment-related risk factors were detected by univariate and multivariate analyses. 175 out of 806 patients receiving TRT with post-treatment imaging were included. 51 patients (24.9%) developed RIPE; 40 had symptomatic RIPE including chest pain (47.1%), cough (23.5%) and dyspnea (35.3%). Female (OR = 0.380, 95% CI: 0.156-0.926, p = 0.033) and Caucasian race (OR = 3.519, 95% CI: 1.327-9.336, p = 0.011) were significantly associated with lower risk of RIPE. Stage and concurrent chemotherapy had borderline significance (OR = 1.665, p = 0.069 and OR = 2.580, p = 0.080, respectively) for RIPE. Patients with RIPE had significantly higher whole lung V5-V40, V50 and MLD. V5 remained as a significant predictive factor for RIPE and symptomatic RIPE (p = 0.007 and 0.022) after adjusting for race, gender and histology. To include, the incidence of RIPE is notable. Whole lung V5 appeared to be the most significant independent risk factor for symptomatic RIPE.

Original languageEnglish (US)
Pages (from-to)97623-97632
Number of pages10
JournalOncotarget
Volume8
Issue number57
DOIs
StatePublished - Jan 1 2017

Fingerprint

Pleural Effusion
Lung Neoplasms
Thorax
Radiation
Lung
Radiotherapy
Fluorodeoxyglucose F18
Chest Pain
Cough
ROC Curve
Dyspnea
Histology
Multivariate Analysis
Tomography
Drug Therapy

Keywords

  • Lung cancer
  • Overall survival
  • Radiation induced pleural effusion
  • Risk factors
  • Thoracic radiotherapy

ASJC Scopus subject areas

  • Oncology

Cite this

Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer. / Zhao, Jing; Day, Regina M.; Jin, JianYue; Quint, Leslie; Williams, Hadyn T; Ferguson, Catherine Lowrie; Yan, Li; King, Maurice; Albsheer, Ahmad; Matuszak, Martha; Kong, Feng Ming.

In: Oncotarget, Vol. 8, No. 57, 01.01.2017, p. 97623-97632.

Research output: Contribution to journalArticle

Zhao, J, Day, RM, Jin, J, Quint, L, Williams, HT, Ferguson, CL, Yan, L, King, M, Albsheer, A, Matuszak, M & Kong, FM 2017, 'Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer', Oncotarget, vol. 8, no. 57, pp. 97623-97632. https://doi.org/10.18632/oncotarget.18824
Zhao, Jing ; Day, Regina M. ; Jin, JianYue ; Quint, Leslie ; Williams, Hadyn T ; Ferguson, Catherine Lowrie ; Yan, Li ; King, Maurice ; Albsheer, Ahmad ; Matuszak, Martha ; Kong, Feng Ming. / Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer. In: Oncotarget. 2017 ; Vol. 8, No. 57. pp. 97623-97632.
@article{8bfa29743f56400c8c7fb177d1ad8bf7,
title = "Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer",
abstract = "The risk factors and potential practice implications of radiation-induced pleural effusion (RIPE) are undefined. This study examined lung cancer patients treated with thoracic radiation therapy (TRT) having follow-up computed tomography (CT) or 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Increased volumes of pleural effusion after TRT without evidence of tumor progression was considered RIPE. Parameters of lung dose-volume histogram including percent volumes irradiated with 5-55 Gy (V5-V55) and mean lung dose (MLD) were analyzed by receiver operating characteristic analysis. Clinical and treatment-related risk factors were detected by univariate and multivariate analyses. 175 out of 806 patients receiving TRT with post-treatment imaging were included. 51 patients (24.9{\%}) developed RIPE; 40 had symptomatic RIPE including chest pain (47.1{\%}), cough (23.5{\%}) and dyspnea (35.3{\%}). Female (OR = 0.380, 95{\%} CI: 0.156-0.926, p = 0.033) and Caucasian race (OR = 3.519, 95{\%} CI: 1.327-9.336, p = 0.011) were significantly associated with lower risk of RIPE. Stage and concurrent chemotherapy had borderline significance (OR = 1.665, p = 0.069 and OR = 2.580, p = 0.080, respectively) for RIPE. Patients with RIPE had significantly higher whole lung V5-V40, V50 and MLD. V5 remained as a significant predictive factor for RIPE and symptomatic RIPE (p = 0.007 and 0.022) after adjusting for race, gender and histology. To include, the incidence of RIPE is notable. Whole lung V5 appeared to be the most significant independent risk factor for symptomatic RIPE.",
keywords = "Lung cancer, Overall survival, Radiation induced pleural effusion, Risk factors, Thoracic radiotherapy",
author = "Jing Zhao and Day, {Regina M.} and JianYue Jin and Leslie Quint and Williams, {Hadyn T} and Ferguson, {Catherine Lowrie} and Li Yan and Maurice King and Ahmad Albsheer and Martha Matuszak and Kong, {Feng Ming}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.18824",
language = "English (US)",
volume = "8",
pages = "97623--97632",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "57",

}

TY - JOUR

T1 - Thoracic radiation-induced pleural effusion and risk factors in patients with lung cancer

AU - Zhao, Jing

AU - Day, Regina M.

AU - Jin, JianYue

AU - Quint, Leslie

AU - Williams, Hadyn T

AU - Ferguson, Catherine Lowrie

AU - Yan, Li

AU - King, Maurice

AU - Albsheer, Ahmad

AU - Matuszak, Martha

AU - Kong, Feng Ming

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The risk factors and potential practice implications of radiation-induced pleural effusion (RIPE) are undefined. This study examined lung cancer patients treated with thoracic radiation therapy (TRT) having follow-up computed tomography (CT) or 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Increased volumes of pleural effusion after TRT without evidence of tumor progression was considered RIPE. Parameters of lung dose-volume histogram including percent volumes irradiated with 5-55 Gy (V5-V55) and mean lung dose (MLD) were analyzed by receiver operating characteristic analysis. Clinical and treatment-related risk factors were detected by univariate and multivariate analyses. 175 out of 806 patients receiving TRT with post-treatment imaging were included. 51 patients (24.9%) developed RIPE; 40 had symptomatic RIPE including chest pain (47.1%), cough (23.5%) and dyspnea (35.3%). Female (OR = 0.380, 95% CI: 0.156-0.926, p = 0.033) and Caucasian race (OR = 3.519, 95% CI: 1.327-9.336, p = 0.011) were significantly associated with lower risk of RIPE. Stage and concurrent chemotherapy had borderline significance (OR = 1.665, p = 0.069 and OR = 2.580, p = 0.080, respectively) for RIPE. Patients with RIPE had significantly higher whole lung V5-V40, V50 and MLD. V5 remained as a significant predictive factor for RIPE and symptomatic RIPE (p = 0.007 and 0.022) after adjusting for race, gender and histology. To include, the incidence of RIPE is notable. Whole lung V5 appeared to be the most significant independent risk factor for symptomatic RIPE.

AB - The risk factors and potential practice implications of radiation-induced pleural effusion (RIPE) are undefined. This study examined lung cancer patients treated with thoracic radiation therapy (TRT) having follow-up computed tomography (CT) or 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT. Increased volumes of pleural effusion after TRT without evidence of tumor progression was considered RIPE. Parameters of lung dose-volume histogram including percent volumes irradiated with 5-55 Gy (V5-V55) and mean lung dose (MLD) were analyzed by receiver operating characteristic analysis. Clinical and treatment-related risk factors were detected by univariate and multivariate analyses. 175 out of 806 patients receiving TRT with post-treatment imaging were included. 51 patients (24.9%) developed RIPE; 40 had symptomatic RIPE including chest pain (47.1%), cough (23.5%) and dyspnea (35.3%). Female (OR = 0.380, 95% CI: 0.156-0.926, p = 0.033) and Caucasian race (OR = 3.519, 95% CI: 1.327-9.336, p = 0.011) were significantly associated with lower risk of RIPE. Stage and concurrent chemotherapy had borderline significance (OR = 1.665, p = 0.069 and OR = 2.580, p = 0.080, respectively) for RIPE. Patients with RIPE had significantly higher whole lung V5-V40, V50 and MLD. V5 remained as a significant predictive factor for RIPE and symptomatic RIPE (p = 0.007 and 0.022) after adjusting for race, gender and histology. To include, the incidence of RIPE is notable. Whole lung V5 appeared to be the most significant independent risk factor for symptomatic RIPE.

KW - Lung cancer

KW - Overall survival

KW - Radiation induced pleural effusion

KW - Risk factors

KW - Thoracic radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=85033781052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85033781052&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18824

DO - 10.18632/oncotarget.18824

M3 - Article

VL - 8

SP - 97623

EP - 97632

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 57

ER -